Clinical trial
A Phase Ib Dose-Escalation Study to Assess the Safety and Tolerability of DV-601 in Subjects With Chronic Hepatitis B on Concurrent Treatment With a Nucleoside Analogue
NCT01023230 is registered in ClinicalTrials.gov with Dynavax Technologies Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib Dose-Escalation Study to Assess the Safety and Tolerability of DV-601 in Subjects With Chronic Hepatitis B on Concurrent Treatment With a Nucleoside Analogue
- Lead sponsor
- Dynavax Technologies Corporation
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2009
- Completion date
- May 31, 2011
- Enrollment
- 14 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.